Several U.S. senators sent a letter to the Federal Trade Commission asking it to closely scrutinize large pharmaceutical mergers and acquisitions according to STAT.
The lawmakers specifically mentioned two pending deals — AbbVie's acquisition of Allergan and Bristol-Myers Squibb's acquisition of Celegene.
In arguing for more scrutiny, lawmakers raised concerns that a lack of competition could cause a rise in drug prices and a lack of accessibility to essential medicines, as well as to lower-cost biosimilars and generics, according to STAT.
They also are concerned the deals may reduce innovation or push drugmakers to more aggressively pursue rebate traps.
Read the full article here.
More articles on pharmacy:
California biotech files for bankruptcy
Ohio's Medicaid director may give results of drug pricing report in front of oversight committee
Q2 brings smaller hikes to wholesale, net drug prices
California biotech files for bankruptcy
Ohio's Medicaid director may give results of drug pricing report in front of oversight committee
Q2 brings smaller hikes to wholesale, net drug prices